**Shortage of Zypadhera (olanzapine)**
*Powder and solvent for prolonged-release suspension for injection (210 mg, 300 mg and 405 mg)*

<table>
<thead>
<tr>
<th>What is Zypadhera used for?</th>
<th>Zypadhera is used to maintain the improvement of symptoms in patients with schizophrenia who have already been stabilised on an initial course of olanzapine taken by mouth. For further information on the use of the medicine please refer to the medicine’s overview page.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reason for shortage</td>
<td>The company making Zypadhera is experiencing manufacturing problems with the 50 mm needles provided with the medicine for the injection. This has led to supply constraints and intermittent shortages of all Zypadhera strengths. The shortage is not related to a quality defect of the product or a safety issue. In order to reduce the impact of the shortage on patients, Zypadhera will temporarily be distributed with three 38 mm safety needles instead of two 38 mm and two 50 mm safety needles.</td>
</tr>
<tr>
<td>Member States affected</td>
<td>The shortage affects all EU/EEA Member States where the product is marketed. This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.</td>
</tr>
<tr>
<td>Monitoring of shortage</td>
<td>EMA’s SPOC working party is closely monitoring the supply situation and engaging with the marketing authorisation holder to identify measures to mitigate the impact of the supply shortage. The SPOC working party is responsible for monitoring and reporting events that could affect the supply of medicines in the EU. Summaries of the SPOC working party meetings can be found on EMA’s website.</td>
</tr>
</tbody>
</table>
| Information to healthcare professionals | • Due to manufacturing problems with the 50 mm needles provided with Zypadhera, the medicine will temporarily be provided with three 38 mm safety needles instead of two 38 mm and two 50 mm safety needles.  
• These three 38 mm safety needles ensure that the medicine can be used in normal-weight patients.  
• For patients with obesity, healthcare professionals should use 19-gauge, 50 mm needles which need to be procured separately. |
### Shortage of Zypadhera (olanzapine)

**Powder and solvent for prolonged-release suspension for injection (210 mg, 300 mg and 405 mg)**

- A direct healthcare professional communication (DHPC) has been sent to relevant healthcare professionals with instructions on how to use the 3 needles and is also available on the [EMA website](https://www.ema.europa.eu).
- For additional information, consult your country’s [shortage register](https://www.ema.europa.eu) or contact your [national competent authority](https://www.ema.europa.eu).

#### Information to patients and carers

- Due to manufacturing problems with the 50 mm needles provided with Zypadhera, the medicine will temporarily be provided with three 38 mm safety needles instead of two 38 mm and two 50 mm safety needles.
- If you are of normal weight, three 38 mm safety needles are sufficient to ensure the medicine can be used normally. If you have obesity your healthcare professional will have to use 19-gauge, 50 mm needles provided separately so that the medicine can be given normally.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s [shortage register](https://www.ema.europa.eu) or contact your [national competent authority](https://www.ema.europa.eu).

#### Status

Ongoing